Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharma

Posted in Biotech by Medtech[y] Staff

September 23, 2019 • 2 min read

Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals Clovis currently planning to file an IND for FAP-targeted radiopharmaceutical therapy in 2H 2020 FAP highly expressed in multiple tumor types; Clovis to pursue broad and accelerated clinical development program...


Medtronic Announces FDA Approval and U.S. Launch of Next-Generation Evolut PRO+ TAVR System for Treatment of Symptomatic Severe Aortic Stenosis Patients

Posted in Medical Device by Medtech[y] Staff

September 23, 2019 • 2 min read

Medtronic plc (NYSE:MDT), a global leader in heart valve therapies, today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut PRO+ TAVR System – a new-generation Medtronic TAVR system that builds off the proven self-expanding, supra-annular Evolut TAVR platform....


Viseon, Inc. Announces US FDA Clearance and Clinical Use of its Advanced High-Definition Real Time Imaging Technology for Minimally Invasive Spine Surgery

Posted in Medical Device by Medtech[y] Staff

September 19, 2019 • 2 min read

​Viseon, Inc. today announced US FDA clearance and initial clinical use of their Voyant System, integrating minimally invasive surgical (MIS) access with real time high definition imaging technology for more efficient procedural workflow, which enhances a clinician’s intraoperative visualization, providing a more accurate, precise ...

Tandem Diabetes Care Announces Publication of Real-world Basal-IQ Predictive Low Glucose Suspend Technology Data in Diabetes Technology and Therapeutics Journal

Posted in Medical Device by Medtech[y] Staff

September 19, 2019 • 2 min read

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of real-world data from more than 8,000 users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend technology in the medical journal Diabetes Technology and Therapeutics...